$3.71 Billion is the total value of BVF INC/IL's 69 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 14.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MOONLAKE IMMUNOTHERAPEUTICSclass a ord | $1,239,823,188 | +11.8% | 21,751,284 | 0.0% | 33.43% | +8.1% | ||
| IONS | Buy | IONIS PHARMACEUTICALS INC | $181,649,246 | +55.6% | 4,004,613 | +40.7% | 4.90% | +50.5% |
| AXSM | AXSOME THERAPEUTICS INC | $148,942,579 | -2.7% | 2,131,100 | 0.0% | 4.02% | -5.9% | |
| IDYA | Sell | IDEAYA BIOSCIENCES INC | $142,548,533 | +6.7% | 5,283,489 | -7.0% | 3.84% | +3.3% |
| MIRM | New | MIRUM PHARMACEUTICALS INC | $138,092,758 | – | 4,370,024 | +100.0% | 3.72% | – |
| OLMA | Buy | OLEMA PHARMACEUTICALS INC | $112,828,279 | +64.2% | 9,135,893 | +20.0% | 3.04% | +58.8% |
| RVMD | Sell | REVOLUTION MEDICINES INC | $110,199,948 | -34.1% | 3,981,212 | -36.4% | 2.97% | -36.3% |
| RPTX | REPARE THERAPEUTICS INC | $100,167,215 | +14.2% | 8,291,988 | 0.0% | 2.70% | +10.5% | |
| PTGX | Buy | PROTAGONIST THERAPEUTICS INC | $95,824,065 | -8.1% | 5,744,848 | +52.1% | 2.58% | -11.1% |
| GHRS | GH RESEARCH PLCordinary shares | $93,215,338 | -15.3% | 9,275,158 | 0.0% | 2.51% | -18.0% | |
| STRUCTURE THERAPEUTICS INCsponsored ads | $88,235,000 | +21.3% | 1,750,000 | 0.0% | 2.38% | +17.3% | ||
| PNT | POINT BIOPHARMA GLOBAL INC | $70,460,199 | -26.4% | 10,563,748 | 0.0% | 1.90% | -28.8% | |
| GLPG | Sell | GALAPAGOS NVspon adr | $66,167,016 | -24.8% | 1,915,109 | -11.5% | 1.78% | -27.3% |
| KYMR | KYMERA THERAPEUTICS INC | $65,872,156 | -39.5% | 4,739,004 | 0.0% | 1.78% | -41.5% | |
| MRUS | Buy | MERUS N V | $64,902,064 | +53.8% | 2,752,420 | +71.8% | 1.75% | +48.8% |
| XENE | XENON PHARMACEUTICALS INC | $62,443,045 | -11.3% | 1,827,958 | 0.0% | 1.68% | -14.2% | |
| KURA | KURA ONCOLOGY INC | $61,386,565 | -13.8% | 6,730,983 | 0.0% | 1.66% | -16.6% | |
| CNTA | Sell | CENTESSA PHARMACEUTICALS PLCsponsored ads | $58,896,759 | +1.0% | 9,103,054 | -3.4% | 1.59% | -2.3% |
| XOMA | XOMA CORP DEL | $51,199,439 | -25.4% | 3,633,743 | 0.0% | 1.38% | -27.8% | |
| FDMT | 4D MOLECULAR THERAPEUTICS IN | $51,014,367 | -29.6% | 4,007,413 | 0.0% | 1.38% | -31.8% | |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $48,393,442 | +38.9% | 7,064,736 | +110.2% | 1.30% | +34.4% |
| JANX | Buy | JANUX THERAPEUTICS INC | $46,164,565 | -5.3% | 4,579,818 | +11.5% | 1.24% | -8.4% |
| TYRA BIOSCIENCES INC | $37,724,223 | -19.1% | 2,739,595 | 0.0% | 1.02% | -21.8% | ||
| ZYMEWORKS INC | $37,215,800 | -26.6% | 5,870,000 | 0.0% | 1.00% | -29.0% | ||
| REPL | REPLIMUNE GROUP INC | $36,667,346 | -26.3% | 2,143,036 | 0.0% | 0.99% | -28.7% | |
| New | ROIVANT SCIENCES LTD | $32,031,337 | – | 2,742,409 | +100.0% | 0.86% | – | |
| CGEM | CULLINAN ONCOLOGY INC | $28,930,144 | -15.9% | 3,196,701 | 0.0% | 0.78% | -18.7% | |
| ETNB | 89BIO INC | $28,504,618 | -18.5% | 1,846,154 | 0.0% | 0.77% | -21.1% | |
| THIRD HARMONIC BIO INC | $27,898,312 | +32.8% | 4,365,933 | 0.0% | 0.75% | +28.5% | ||
| EPIX | ESSA PHARMA INC | $27,033,264 | +14.4% | 8,748,629 | 0.0% | 0.73% | +10.8% | |
| OVID | OVID THERAPEUTICS INC | $26,308,036 | +17.1% | 6,851,051 | 0.0% | 0.71% | +13.3% | |
| AN2 THERAPEUTICS INC | $25,148,525 | +89.2% | 1,563,963 | 0.0% | 0.68% | +82.7% | ||
| LXRX | LEXICON PHARMACEUTICALS INC | $21,794,912 | -52.4% | 19,995,332 | 0.0% | 0.59% | -53.9% | |
| ACIU | AC IMMUNE SA | $21,170,880 | -3.6% | 7,428,379 | 0.0% | 0.57% | -6.7% | |
| RLAY | Sell | RELAY THERAPEUTICS INC | $19,896,420 | -49.2% | 2,365,805 | -24.2% | 0.54% | -50.8% |
| ALLK | Sell | ALLAKOS INC | $19,413,987 | -48.5% | 8,552,417 | -1.2% | 0.52% | -50.1% |
| SLN | SILENCE THERAPEUTICS PLCads | $14,827,729 | +78.7% | 1,508,416 | 0.0% | 0.40% | +73.2% | |
| GLYC | GLYCOMIMETICS INC | $14,316,393 | -13.8% | 9,544,262 | 0.0% | 0.39% | -16.6% | |
| NEWAMSTERDAM PHARMA COMPANYordinary shares | $14,078,019 | -22.2% | 1,521,948 | 0.0% | 0.38% | -24.6% | ||
| ITOS | Sell | ITEOS THERAPEUTICS INC | $13,791,262 | -42.5% | 1,259,476 | -30.4% | 0.37% | -44.3% |
| IKNA | IKENA ONCOLOGY INC | $13,722,480 | -34.0% | 3,169,164 | 0.0% | 0.37% | -36.1% | |
| VERASTEM INC | $13,700,830 | +9.3% | 1,685,219 | 0.0% | 0.37% | +5.7% | ||
| CALT | CALLIDITAS THERAPEUTICS ABsponsered ads | $13,695,000 | +16.3% | 750,000 | 0.0% | 0.37% | +12.5% | |
| STRO | SUTRO BIOPHARMA INC | $11,617,373 | -25.4% | 3,347,946 | 0.0% | 0.31% | -27.9% | |
| IMVT | New | IMMUNOVANT INC | $11,517,000 | – | 300,000 | +100.0% | 0.31% | – |
| VIGIL NEUROSCIENCE INC | $9,775,482 | -42.7% | 1,813,633 | 0.0% | 0.26% | -44.4% | ||
| VERV | VERVE THERAPEUTICS INC | $8,619,000 | -29.3% | 650,000 | 0.0% | 0.23% | -31.8% | |
| CTMX | CYTOMX THERAPEUTICS INC | $8,508,583 | -25.0% | 6,595,801 | 0.0% | 0.23% | -27.5% | |
| TSCAN THERAPEUTICS INC | $7,653,053 | +2.4% | 2,989,474 | 0.0% | 0.21% | -1.0% | ||
| JASPER THERAPEUTICS INC | $6,930,000 | -48.9% | 9,900,000 | 0.0% | 0.19% | -50.5% | ||
| CDTX | CIDARA THERAPEUTICS INC | $6,464,554 | -16.6% | 6,861,127 | 0.0% | 0.17% | -19.4% | |
| PIRS | PIERIS PHARMACEUTICALS INC | $6,141,739 | +80.1% | 20,609,863 | 0.0% | 0.17% | +74.7% | |
| ELDN | ELEDON PHARMACEUTICALS INC | $5,927,593 | 0.0% | 4,326,710 | 0.0% | 0.16% | -3.0% | |
| NLSP | NLS PHARMACEUTICS LTD | $3,970,689 | -37.2% | 5,747,126 | 0.0% | 0.11% | -39.2% | |
| DCTH | Sell | DELCATH SYS INC | $3,953,403 | -42.5% | 976,149 | -17.2% | 0.11% | -44.3% |
| KRON | Buy | KRONOS BIO INC | $3,776,556 | -22.0% | 2,905,043 | +3.3% | 0.10% | -24.4% |
| VIRX | VIRACTA THERAPEUTICS INC | $3,759,248 | -26.2% | 3,614,662 | 0.0% | 0.10% | -28.9% | |
| New | MOLECULAR TEMPLATES INC | $3,362,480 | – | 532,038 | +100.0% | 0.09% | – | |
| RAIN | RAIN ONCOLOGY INC | $3,039,335 | -28.2% | 3,526,729 | 0.0% | 0.08% | -30.5% | |
| New | UNICYCIVE THERAPEUTICS INC | $2,935,664 | – | 3,413,563 | +100.0% | 0.08% | – | |
| IVA | INVENTIVA SAads | $2,881,368 | +4.0% | 686,040 | 0.0% | 0.08% | +1.3% | |
| CRVS | CORVUS PHARMACEUTICALS INC | $2,001,583 | -36.2% | 1,370,947 | 0.0% | 0.05% | -38.6% | |
| FBRX | New | FORTE BIOSCIENCES INC | $1,974,154 | – | 2,982,105 | +100.0% | 0.05% | – |
| ASLAN PHARMACEUTICALS LTDspon ads new | $1,942,498 | -49.3% | 1,049,999 | 0.0% | 0.05% | -51.4% | ||
| MOLN | MOLECULAR PARTNERS AGads | $1,768,452 | -34.7% | 443,221 | 0.0% | 0.05% | -36.0% | |
| IMUX | IMMUNIC INC | $1,689,655 | -41.4% | 1,149,425 | 0.0% | 0.05% | -42.5% | |
| ELEV | ELEVATION ONCOLOGY INC | $1,532,064 | -56.4% | 2,312,200 | 0.0% | 0.04% | -58.2% | |
| RZLT | REZOLUTE INC | $251,876 | -33.3% | 190,815 | 0.0% | 0.01% | -36.4% | |
| Sell | BIONOMICS LIMITEDads | $127,904 | -28.2% | 47,372 | -41.5% | 0.00% | -40.0% | |
| Exit | GALMED PHARMACEUTICALS LTD | $0 | – | -89,853 | -100.0% | -0.01% | – | |
| INFI | Exit | INFINITY PHARMACEUTICALS INC | $0 | – | -6,353,645 | -100.0% | -0.04% | – |
| MTEM | Exit | MOLECULAR TEMPLATES INC | $0 | – | -4,996,565 | -100.0% | -0.07% | – |
| ARAV | Exit | ARAVIVE INC | $0 | – | -4,784,214 | -100.0% | -0.17% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 36 | Q3 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 30 | Q3 2023 | 2.8% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| XOMA CORP DEL | 28 | Q3 2023 | 7.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| CHEMOCENTRYX INC | 26 | Q3 2019 | 13.8% |
| CYTOMX THERAPEUTICS INC | 26 | Q3 2023 | 5.3% |
| CORVUS PHARMACEUTICALS INC | 26 | Q3 2023 | 2.3% |
| ARRAY BIOPHARMA INC | 25 | Q2 2019 | 14.5% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 4 | 2024-01-29 |
| 3 | 2024-01-26 |
| 4 | 2024-01-09 |
| 4 | 2023-12-20 |
| 4 | 2023-11-17 |
| 13F-HR | 2023-11-14 |
| 3 | 2023-11-13 |
| 3 | 2023-11-06 |
| 4 | 2023-11-06 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.